Similar articles

• Secondary prevention of myocardial infarction. Comparison of acetylsalicylic acid, phenprocoumon and placebo. A multicenter two-year prospective study.

  Breddin K, Loew D, Lechner K, Uberla K, Walter E. Breddin K, et al. Thromb Haemost. 1979 Feb 28;41(1):225-36. Thromb Haemost. 1979. PMID: 483232 Clinical Trial. No abstract available.
• [Prevention of sequelae after myocardial infarct. Results, methods and problems of a prospective multi-center study of the effect of acetylsalicylic acid, phenprocoumon and placebo].

  Breddin HK, Uberla KK. Breddin HK, et al. Verh Dtsch Ges Inn Med. 1980;86:1338-48. Verh Dtsch Ges Inn Med. 1980. PMID: 7013326 Clinical Trial. German. No abstract available.
• [Course control of platelet function and blood lipid levels during a 2 years prospective study on the prevention of reinfarction with acetylsalicylic acid, phenprocoumon and placebo].

  Walter E, Weber E, Loew D. Walter E, et al. Verh Dtsch Ges Inn Med. 1978;(84):1481-5. Verh Dtsch Ges Inn Med. 1978. PMID: 369187 Clinical Trial. German. No abstract available.
• Clinical trials of antiplatelet drug therapy in acute myocardial infarction, unstable angina, and aortocoronary bypass surgery.

  Cairns JA. Cairns JA. Cardiovasc Clin. 1987;18(1):231-46. Cardiovasc Clin. 1987. PMID: 3300983 Review. No abstract available.
• [The Brisighella study. II. Metabolic risk factors].

  Descovich GC, Gaddi A, Mannino G, Lenzi S. Descovich GC, et al. G Ital Cardiol. 1981;11(11):1591-603. G Ital Cardiol. 1981. PMID: 7044862 Review. Italian.